Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Clinical Activity, Safety Profile, and Pharmacology of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

NCT06922539 is registered in ClinicalTrials.gov with SciTech Development, Inc. as lead sponsor.

NCT NCT06922539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06922539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Clinical Activity, Safety Profile, and Pharmacology of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
Lead sponsor
SciTech Development, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 11, 2025
Completion date
October 1, 2028
Enrollment
44 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer